Anavex Life Sciences Stock EBITDA
AVXL Stock | USD 9.46 0.43 4.76% |
Anavex Life Sciences fundamentals help investors to digest information that contributes to Anavex Life's financial success or failures. It also enables traders to predict the movement of Anavex Stock. The fundamental analysis module provides a way to measure Anavex Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anavex Life stock.
Last Reported | Projected for Next Year | ||
EBITDA | -42.7 M | -40.6 M |
Anavex | EBITDA |
Anavex Life Sciences Company EBITDA Analysis
Anavex Life's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Anavex Life EBITDA | (47.5 M) |
Most of Anavex Life's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anavex Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Anavex EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Anavex Life is extremely important. It helps to project a fair market value of Anavex Stock properly, considering its historical fundamentals such as EBITDA. Since Anavex Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Anavex Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Anavex Life's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition |
Anavex Ebitda
According to the company disclosure, Anavex Life Sciences reported earnings before interest,tax, depreciation and amortization of (47.5 Million). This is 105.41% lower than that of the Biotechnology sector and 147.42% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.22% higher than that of the company.
Anavex EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anavex Life's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Anavex Life could also be used in its relative valuation, which is a method of valuing Anavex Life by comparing valuation metrics of similar companies.Anavex Life is currently under evaluation in ebitda category among its peers.
Anavex Life Current Valuation Drivers
We derive many important indicators used in calculating different scores of Anavex Life from analyzing Anavex Life's financial statements. These drivers represent accounts that assess Anavex Life's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Anavex Life's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 154.5M | 264.8M | 793.7M | 522.6M | 470.3M | 493.9M | |
Enterprise Value | 132.4M | 235.5M | 644.6M | 371.6M | 334.4M | 351.1M |
Anavex Life ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Anavex Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Anavex Life's managers, analysts, and investors.Environmental | Governance | Social |
Anavex Life Institutional Holders
Institutional Holdings refers to the ownership stake in Anavex Life that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Anavex Life's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Anavex Life's value.Shares | Oz Management Llc | 2024-09-30 | 370.4 K | Nuveen Asset Management, Llc | 2024-06-30 | 304.2 K | Bank Of New York Mellon Corp | 2024-06-30 | 280.6 K | Susquehanna International Group, Llp | 2024-06-30 | 264.4 K | Renaissance Technologies Corp | 2024-09-30 | 243.8 K | Jane Street Group Llc | 2024-06-30 | 181.9 K | Ubs Group Ag | 2024-06-30 | 142.6 K | Rafferty Asset Management, Llc | 2024-09-30 | 139.6 K | Exoduspoint Capital Management, Lp | 2024-09-30 | 127.3 K | Blackrock Inc | 2024-06-30 | 6.4 M | Vanguard Group Inc | 2024-09-30 | 4.7 M |
Anavex Fundamentals
Return On Equity | -0.3 | ||||
Return On Asset | -0.2 | ||||
Current Valuation | 626.95 M | ||||
Shares Outstanding | 84.8 M | ||||
Shares Owned By Insiders | 3.04 % | ||||
Shares Owned By Institutions | 32.00 % | ||||
Number Of Shares Shorted | 18.81 M | ||||
Price To Earning | (11.03) X | ||||
Price To Book | 5.90 X | ||||
EBITDA | (47.5 M) | ||||
Net Income | (47.51 M) | ||||
Cash And Equivalents | 149.16 M | ||||
Cash Per Share | 1.91 X | ||||
Total Debt | 12.53 M | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 14.95 X | ||||
Book Value Per Share | 1.53 X | ||||
Cash Flow From Operations | (27.79 M) | ||||
Short Ratio | 13.65 X | ||||
Earnings Per Share | (0.51) X | ||||
Target Price | 35.47 | ||||
Number Of Employees | 40 | ||||
Beta | 0.6 | ||||
Market Capitalization | 765.7 M | ||||
Total Asset | 154.39 M | ||||
Retained Earnings | (293.07 M) | ||||
Working Capital | 141.85 M | ||||
Current Asset | 9.45 M | ||||
Current Liabilities | 3.19 M | ||||
Net Asset | 154.39 M |
About Anavex Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anavex Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anavex Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anavex Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Anavex Life Piotroski F Score and Anavex Life Altman Z Score analysis. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Return On Assets (0.20) | Return On Equity (0.30) |
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.